Optimal stimulation sites of the subthalamic nucleus for the treatment of gait symptoms of Parkinson's disease

Zhongke Mei[1], Anna-Sophie Hofer[2,3], Christian Baumann[4], Mechtild Uhl[4], Navrag Singh[1,5], William R. Taylor[1,5], Lennart Stieglitz[2], Deepak Ravi[1]

[1] Institute for Biomechanics, ETH Zurich, 8006 Zurich, Switzerland
[2] Department of Neurosurgery, University Hospital Zurich, 8091 Zurich, Switzerland
[3] Department of Neurosurgery, Medical University of Innsbruck, 6020 Innsbruck, Austria
[4] Department of Neurology, University Hospital Zurich, 8091 Zurich, Switzerland
[5] Singapore-ETH Centre, Future Health Technologies Program, CREATE campus, 1 CREATE Way, #06-01 CREATE Tower, Singapore 138602

Corresponding Author

Dr. Deepak Ravi
Institute for Biomechanics
ETH Zürich
Email: deepak.ravi@hest.ethz.ch

Running Title: Optimal STN stimulation sites for gait performance

Keywords: Parkinson's disease, deep brain stimulation, subthalamic nucleus, stimulation site, gait performance

Author contributions:
DR, ZM, ASH, and LS conceived and designed the study. CB, LS, and MU coordinated the recruitment, pre-surgery, and post-surgery of the participants. DR, NS, and WT coordinated the gait measurements. ASH and LS performed the lead localisation reconstruction. ZM and DR analysed the data. ZM, DR and ASH drafted the manuscript. All the authors reviewed, provided critical opinion, and approved the final version of the manuscript for submission. WRT is the guarantor.

Data Availability:
Due to ethical considerations, open publication of the dataset for further use by researchers outside of the investigating team is not possible. Please contact the corresponding author for collaborations and requests.

Abstract

Deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) is a widely adopted therapy for mitigating motor symptoms in Parkinson's Disease (PD). Although the electrode placement site has been proposed as a significant factor influencing motor outcomes, the specific relationships between electrode location and therapeutic effects on gait performance remain unclear. This study seeks to identify optimal stimulation sites within the STN to effectively address gait symptoms in patients with PD (PwPD). We assessed overground gait performance in 49 PwPD who underwent bilateral STN-DBS surgery, both before treatment initiation and six months post-implantation, comparing the results to 51 asymptomatic individuals. Our evaluation focused on treatment-induced changes in the mean (mean set) and coefficient of variability (variability set) of ten commonly used spatio-temporal gait parameters, such as stride length and walking speed. We also examined their correlation with the location of the active contacts of the DBS electrodes utilized for therapeutic stimulation. Our findings indicate that DBS treatment resulted in a significant reduction in stride time, stance time, swing time, and step time, in addition to an increase in the variability of double limb stance time, stride time, stance time, and step time. Furthermore, we observed that the location of the active contacts resulted in alterations in mean step length, stride length, and walking speed, as well as changes to cadence, stride time, stance time, and step width. We identified the postero-superior region of the STN as the most effective region for improving the mean set, whereas the antero-superior region of the STN emerged as the most effective region for improving the variability set. This study provides empirical evidence on how STN-DBS, in tandem with the location of active lead contacts, impacts both mean and variability of spatio-temporal gait parameters in PwPD. Importantly, our results indicate specific STN spatial targets for DBS implantation to address patient specific gait symptoms.

1. Introduction

Parkinson's disease (PD) is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age[1]. The pathogenesis of PD involves neuronal loss in specific areas of the substantia nigra and widespread intracellular protein accumulation, leading to various pathological motor and non-motor symptoms, including gait deficiency[2]. Deep brain stimulation of the subthalamic nucleus (STN-DBS) has been proven effective for treating motor symptoms in PD. Several studies suggest that STN-DBS improves dopamine-responsive motor symptoms on the motor part (III) of the Unified Parkinson Disease Rating Scale (UPDRS) by reducing pathological motor symptoms such as akinesia, rigidity, and tremor[3-6]. However, the UPDRS oversimplifies gait symptoms, and planning surgery based on these unspecific scores may cause variable treatment outcomes in patients with PD (PwPD)[7,8]. Therefore, it is still unclear how STN-DBS treatment affects gait performance in PwPD.

With the development of improved imaging and software for lead localization planning and reconstruction[9], the significance of active contact localization for therapeutic outcomes is becoming increasingly evident. A direct involvement of the interface between supero-dorso-lateral STN, zona incerta, and Forel's fields on the motor effects of STN stimulation has been suggested[10-13]. Importantly, recent data has indicated a correlation between gait improvement and location of active contact within the STN of PwPD[14]. Furthermore, meta-analyses suggest that certain stimulation locations affect specific sections of the UPDRS, where distinct 'sweet spots' have been described, e.g., the supero-dorso-medial border of the STN for influencing rigidity and bradykinesia, and the dorsolateral region of the STN for addressing tremor and rigidity[15-17]. We thus hypothesize that stimulation location could also account for varying effects on gait performance observed with STN-DBS. A comprehensive investigation of these relationships, however, is lacking.

In this study, we therefore investigate the impact of STN-DBS on gait performance based on objective gait parameters of PwPD before and six months after initiation of STN-DBS treatment and assess the correlation between treatment-related changes in gait performance and stimulation location. Ultimately, we aim at the definition of the most effective regions for STN-DBS in order to maximize the gait improvement of patients suffering from PD.

2. Methods

2.1 Study Participants

A convenience sample of 49 PwPD (excluding 9 dropouts), who were scheduled for STN-DBS treatment, was recruited at the University Hospital of Zurich in the years 2016 - 2021. The sample consisted of 41 male and 8 female patients, with a mean age of 59.7±10.4 years and a confirmed diagnosis of Parkinson's disease with a disease course of 8.9±4.5 years. Additionally, a group of 51 asymptomatic control participants voluntarily participated in this study. All members of the control group fulfilled the inclusion criteria of age between 40 and 90 years, lack of neurological, psychiatric, and orthopaedic disorders, and the ability to walk independently and continuously for 10 minutes. The control group was comprised of 22 male and 29 female individuals, with a mean age of 66.6±10.7 years. The study was approved (approval no: 201500141) by the Zurich Cantonal Ethics Commission and carried out in

accordance with the Declaration of Helsinki, the guidelines of Good Clinical Practice, and the Swiss regulatory authority's requirements. All participants provided written, informed consent prior to study involvement. The detailed surgical protocol and postoperative management of patients are provided in Supplementary Methods 1. Stimulation parameters are also presented in Supplementary Table 1.

2.2 Image acquisition and localization of active contact

Reconstruction of each electrode's active lead contact localization within the left and right STN was performed using the Brainlab (www.brainlab.com) stereotactic planning software. Each patient's native brain computed tomography (CT) scan and T2-weighted magnetic resonance imaging (MRI) scan (3D vista sequence) were automatically fused, including manual correction if required. Afterwards, automated anatomical mapping was performed, with accuracy of relevant anatomical structure mapping double-checked manually. Next, anterior-commissure to posterior-commissure (AC-PC) lines were inserted based on the patient's MRI using the lead localization function, and electrodes were automatically detected based on the patient's CT scans. For all detected electrodes, properties were set to the Medtronic 3389-lead type. To address the high degree of individuality of STN sizes and shapes between patients, the area in and around STN was divided into 5x5x7(=175) voxels, where the spatial localization of the active stimulation contacts relative to the STN were localized within one voxel of the 5x5x7-field grid instead of general stereotactic coordinates. The plane containing each electrode's active contact centre of cathode stimulation (left electrode, contact 0-3 from electrode tip upwards, e.g., documented as 2-C+; right electrode, contact 8-11 from electrode tip upwards, e.g., documented as 9-C+) was selected in the x-direction (medio-lateral), y-direction (anterior-posterior) and z-direction (superior-inferior). In case two contacts were used for cathode stimulation, e.g., 2-3-C+, the plane centred in the middle between e.g., contact 2 and contact 3, was used for scoring.

Active contact position in the X-direction was scored as follows:

0 = contact completely outside of the STN medially; 1 = contact partially in the STN medially; 2 = contact in the central part of STN; 3 = contact partially in the STN laterally; 4 = contact completely outside of STN laterally.

Active contact position in the Y-direction was scored as follows:

0 = contact completely outside of STN anteriorly; 1 = contact partially in the STN anteriorly; 2 = contact in the anterior third of STN; 3 = contact in the central part of STN; 4 = contact in the posterior third of STN; 5 = contact partially in the STN posteriorly; 6 = contact completely outside of the STN posteriorly.

Active contact position in the Z-direction was scored as follows:

0 = contact completely outside of STN superiorly; 1 = contact partially in the STN superiorly; 2 = contact in the central part of STN; 3 = contact partially in the STN inferiorly; 4 = contact completely outside of STN inferiorly.

An illustrative example of scoring is shown in *Figure 1*.



Figure 1. *Exemplary location of active contacts of STN-DBS electrodes implanted into the (A) right hemisphere and (B) left hemisphere, where the light green lines indicate the boarders of the STN region. (A) Scoring of right-sided electrode with active contact 9 (9-C+, highlighted by horizontal line illustrating plane of analysis): medio-lateral score 2, superior-inferior score 2, anterior-posterior score 4. (B) Scoring of left-sided electrode with active contact 2 (2-C+, highlighted by horizontal line illustrating plane of analysis): medio-lateral score 1, superior-inferior score 2, anterior-posterior score 5.*

2.3 Quantification of gait performance

Gait kinematics were assessed in 49 PwPD before DBS electrode implantation (Pre-DBS) under ON medication, and approximately 6 months after DBS electrode implantation (Post-DBS) under ON medication and ON stimulation. Recruitment and assessment of control participants was performed concurrently. All participants walked barefoot for a continuous period of 10 minutes at a self-selected speed and without any assistance. Each participant was instructed to navigate an "8"-shaped path around two signs positioned 10 meters apart, with the aim of capturing consecutive gait cycles during overground walking in the laboratory setting[18]. Locomotion was recorded using a three-dimensional motion capture camera system (consisting of 10 cameras; 61 markers; sampling rate of 100 Hz; Vicon Nexus, version 2.3/2.8.2, Oxford Metrics, United Kingdom). Prior to recording, all cameras were calibrated with an error threshold set at 0.5 mm. Commonly used spatio-temporal parameters were calculated in MATLAB (version R2022a, The MathWorks Inc., Natick) by selecting the trajectories of the markers mounted to the participant's heel (calcaneus), toe (metatarsal head III), and sacrum (midpoint between left and right posterior superior iliac spines).

In total, 6 temporal parameters (cadence, in steps/min; double limb support time [DLST], stride time, stance time, swing time, and step time, in s), 3 spatial parameters (step length, stride length, and step width, in cm), as well as walking speed (cm/s) were selected to represent the gait performance (Supplementary Methods 2). The mean values and coefficients of variability of each parameter were selected to analyse the change between pre- and post-DBS surgery. The coefficient of variation (defined as standard deviation/mean × 100) was used to represent the variability of gait parameters. Prior to this calculation, we eliminated all outliers that fell outside the range of ±4 median absolute deviations from the median.

2.4 Statistical analysis

Two sample t-tests and chi-squared tests were performed to examine if differences in demographics existed between PwPD before DBS surgery and healthy controls. Significance was set at α=0.01. To investigate the effects of DBS surgery on gait parameters, a paired t-test was conducted between the Pre-DBS and Post-DBS datasets for both mean value and coefficient of variation, using a significance level of α=0.05. Meanwhile, an unpaired t-test was also performed between Post-DBS and healthy control datasets with a significance level of α=0.05. Afterwards, in order to report a measure of precision and confidence about our estimates that is not sensitive to the distribution of the observations or underlying populations, effect sizes were calculated using 5000 times bootstrap resampling, along with the 95% confidence intervals[19]. The effect size was calculated using Hedges' g (and interpreted as a small effect if $0.2<g<0.5$; a medium effect if $0.5\leq g\leq 0.8$; and a large effect if $g>0.8$)[20,21].

Next, the active contact locations were divided into three independent variables: the x-axis (from medial to lateral), y-axis (from anterior to posterior), and z-axis (from superior to inferior). For each gait parameter, the difference between Post-DBS and Pre-DBS was obtained to represent the influence of DBS on each gait parameter. ANOVAs were then performed for each of these parameter differences separately, using the x-axis, y-axis, and z-axis as independent factors. The subgroups (patients with active contacts in the same voxels in the x-, y-, and z-axis, see *Figure 3*) were categorized by voxel numbers in each factor, indicating the stimulation location. The significance level was set at α=0.05. This ANOVA aimed to investigate if there was a significant difference in the changes observed in gait parameters relative to the stimulation locations. The assumption of the homogeneity of variance was checked by Bartlett's test and the assumption of normality was checked by the Shapiro-Wilk test (Supplementary Table 2).

2.5 Most effective region investigation

Based on the ANOVA results, responsive parameters (those sensitive to contact location, that showed significant changes) were categorized into reduced mean and reduced variability sets. Afterwards, the average tendencies along the x-, y-, and z-axes were calculated for each group. Subsequently, the most effective regions were visually defined based on these average tendencies. In case of the mean set, the most effective region was defined as the location where the maximum increase in spatial parameters occurred, hence indicating reduced bradykinesia and enhanced walking stability as individuals enhance their movement amplitude[7,22,23]. For the mean set, the most effective region was determined as the location where the maximum decrease (or minimum increase) in temporal parameters occurred, representing an increase (or limited decrease) in walking stability for the patients[24]. Subsequently, t-tests were conducted for each selected parameter to determine if there was a significant difference between patients with stimulation locations in the most effective region and those without, with a significance level of α=0.05. Statistical analyses were performed using MATLAB (version R2022a, MathWorks Inc.) and R (version 4.3.1, www.r-project.org).

3. Results

3.1 Patient demographics

The demographic characteristics including the mean and standard deviation of age, sex distribution, weight, height, age at time of disease onset, and disease duration and severity degree (Hoehn and Yahr scale) of PwPD vs. demographics of age-matched healthy controls are shown in Table 1.

Table 1. *Baseline and Longitudinal Demographic Characteristics*

Characteristics	**Healthy Controls (N = 51)**	**PwPD Pre-DBS (N = 49)**	**PwPD Post-DBS (N = 49)**	**Healthy Controls vs PwPD Pre-DBS *P*-value**
Age (years)	66.6 (10.7)	59.7 (10.4)	-	< 0.01
Male/Female (No.)	22/29	41/8	-	< 0.01
Weight (kg)	68.1 (12.2)	76.8 (12.6)	78.8 (11.9)	< 0.01
Height (cm)	168.9 (8.8)	176.1 (6.8)	175.7 (7.0)	< 0.01
Age at disease onset (years)	-	50.8 (9.7)	-	-
Disease duration (years)	-	8.9 (4.5)	-	-
H&Y stage	-	2 (1–3)	-	-
MDS-UPDRS III	-	18.89 (6.9)	17.02 (7.9)	-

Values are expressed as numbers of participants or mean (standard deviation). Baseline demographics between the two groups (PwPD Pre-DBS and Healthy Controls) were significantly different (P<0.01, two-sample t-tests and chi-squared tests). Abbreviations: PwPD, patients with Parkinson's disease; DBS, deep brain stimulation; H&Y, Hoehn and Yahr.

3.2 STN-DBS treatment effects on gait performance

The comparison of mean and variability of 10 gait parameters between groups exhibited significant differences between Pre- and Post-DBS surgery *(Figure 2)*.



Figure 2. *The radar plot illustrates (A) mean and (B) variability of 10 gait characteristics for PwPD before (Pre-DBS, red line) and 6 months after (Post-DBS, blue line) DBS surgery as well as age-matched healthy controls (Control, green dotted). The radial scale is based on ±2 times the standard deviation of the control group around the Z-score for each parameter, which was calculated based on the mean and standard deviation of the control group. For example, the mean cadence of PwPD before surgery is low when compared to healthy controls; after DBS surgery, the cadence of PwPD is slightly larger than that of healthy controls. Asterisks represent significant differences between the Pre-DBS and Post-DBS groups.*

With DBS treatment, cadence and step width increased significantly among the mean gait parameters, while stride time, stance time, swing time, and step time significantly decreased

(Table 2). Stride length and step length decreased slightly, but non-significantly. Walking speed and DLST did not differ between Pre-DBS and Post-DBS assessments. Cadence, stride time, swing time, step length, step width, stride length, and walking speed all approached values seen in healthy controls, indicating minimal differences between Post-DBS patients and healthy controls.

Table 2. *The means (SD) of gait parameters for Pre-DBS, Post-DBS, and the control group are depicted, accompanied by effect sizes with confidence intervals and p-values. Statistically significant differences are denoted with bolded numbers.*

Mean Gait Parameters	**Pre-DBS**	**Post-DBS**	**Control**	***p-value* (pre-post)**	***p-value* (post-control)**	**Effect Size (Hedges' g, pre-post)**	**Effect Size Confidence Intervals**
Cadence (steps/min)	113.5 (7.7)	115.8 (6.8)	115.9 (8.2)	**<0.001**	0.908	0.318	(0.090, 0.546)
DLST (s)	0.13 (0.02)	0.12 (0.02)	0.13 (0.02)	0.169	0.490	-0.134	(-0.372, 0.115)
Stride Time (s)	1.06 (0.07)	1.04 (0.06)	1.04 (0.08)	**<0.001**	0.975	-0.319	(-0.549, -0.101)
Stance Time (s)	0.66 (0.05)	0.64 (0.05)	0.65 (0.05)	**0.001**	0.784	-0.268	(-0.503, -0.042)
Swing Time (s)	0.41 (0.02)	0.40 (0.02)	0.40 (0.02)	**<0.001**	0.500	-0.349	(-0.587, -0.100)
Step Length (cm)	64.5 (8.2)	63.5 (8.3)	63.4 (5.9)	0.090	0.870	-0.118	(-0.290, 0.081)
Step Time (s)	0.53 (0.04)	0.51 (0.03)	0.52 (0.04)	**<0.001**	0.969	-0.320	(-0.551, -0.102)
Step Width (cm)	7.8 (3.0)	8.2 (3.1)	7.9 (2.2)	**0.018**	0.407	0.140	(-0.025, 0.292)
Stride Length (cm)	127.8 (16.5)	125.8 (16.7)	125.6 (12.0)	0.066	0.917	-0.123	(-0.296, 0.078)
Walking Speed (cm/s)	120.4 (19.1)	121.3 (18.8)	121.2 (14.4)	0.490	0.968	0.046	(-0.138, 0.244)

The variability of step width decreased significantly with DBS treatment, approaching control group values *(Table 3)*. The variability of DLST, stride time, stance time, and step time all significantly increased with DBS treatment, showing a worsening of most temporal gait variability parameters compared healthy controls. The variability of cadence, swing time, step length, and stride length also increased, but these changes were not affected significantly by DBS treatment. The variability of walking speed showed no significant difference with DBS treatment.

Table 3. *Variability of gait parameters for the Pre-DBS, Post-DBS, and control group are shown. Statistically significant differences are indicated with bolded numbers.*

Parameters of Gait Variability	**Pre-DBS**	**Post-DBS**	**Control**	***p-value* (pre-post)**	***p-value* (post-control)**	**Effect Size (Hedges' g, pre-post)**	**Effect Size Confidence Intervals**
Cadence (% CV)	1.64 (0.68)	1.82 (0.86)	1.60 (0.88)	0.055	0.169	0.228	(-0.102, 0.567)
DLST (% CV)	8.29 (2.39)	9.26 (3.34)	6.81 (2.49)	**0.036**	**0.001**	0.329	(0.005, 0.644)
Stride Time (% CV)	1.96 (0.61)	2.15 (0.82)	1.87 (0.89)	**0.037**	0.088	0.254	(-0.069, 0.598)
Stance Time (% CV)	2.70 (0.74)	3.01 (1.02)	2.48 (1.07)	**0.006**	**0.013**	0.348	(0.035, 0.690)
Swing Time (% CV)	2.54 (0.68)	2.78 (1.02)	2.07 (0.77)	0.065	**0.002**	0.275	(-0.025, 0.580)
Step Length (% CV)	3.52 (1.05)	3.76 (1.31)	2.71 (0.76)	0.085	**<0.001**	0.200	(-0.098, 0.478)
Step Time (% CV)	2.44 (0.59)	2.64 (0.91)	2.22 (0.83)	**0.039**	**0.009**	0.266	(-0.051, 0.595)
Step Width (% CV)	32.69 (15.30)	28.30 (12.97)	25.40 (9.97)	**0.001**	0.306	-0.307	(-0.551, -0.048)
Stride Length (% CV)	3.11 (1.07)	3.32 (1.27)	2.43 (0.83)	0.083	**<0.001**	0.184	(-0.111, 0.473)
Walking Speed (% CV)	4.00 (2.67)	3.91 (1.49)	3.27 (1.54)	0.739	**0.020**	-0.044	(-0.403, 0.339)

3.3 Relationship between changes in gait performance and location of active contacts

The results of the ANOVA indicate that DBS stimulation location resulted in a greater impact on mean spatial parameters than mean temporal parameters *(Table 4)*. Conversely, for gait variability parameters, temporal parameters were more influenced by the stimulation location than spatial parameters. Here, the variabilities of cadence, stride time, and stance

time were significantly affected by the location of active contact along the x-axis, while variability of step width was influenced by active contact location in all three axes. Mean step length was impacted along the z-axis, while mean stride length and walking speed were influenced by active contact location in both the x- and z-axes.

Table 4. *The p-values for the differences in gait parameters according to DBS active contact location along each of the x-, y-, z-axes are provided. Statistically significant differences are indicated with bolded numbers.*

Parameters	**Mean**			**Variability**		
	x-axis	y-axis	z-axis	x-axis	y-axis	z-axis
Cadence	0.156	0.186	0.930	**0.015**	0.366	0.745
DLST	0.191	0.231	0.533	0.484	0.791	0.714
Stride Time	0.248	0.329	0.962	**0.033**	0.231	0.567
Stance Time	0.113	0.391	0.898	**0.043**	0.608	0.421
Swing Time	0.921	0.401	0.586	0.922	0.865	0.781
Step Length	0.065	0.411	**0.010**	0.427	0.840	0.109
Step Time	0.375	0.200	0.992	0.120	0.430	0.857
Step Width	0.179	0.126	0.081	**0.042**	**0.003**	**0.018**
Stride Length	**0.041**	0.243	**0.003**	0.511	0.830	0.052
Walking Speed	**0.010**	0.119	**0.012**	0.350	0.885	0.168

Within the mean parameter group, the relationship between gait parameters and location of active contact exhibited considerable variation across different parameters, with no clear identifiable pattern of parameters showing positive changes (Figure 3, for additional details of the influence of active contact location on each gait parameter see Supplementary Figure 1). In the variability set, with the exception of step width, all parameters showed similar associations with the location of active contacts along the x-, y-, and z-axes, all sharing the same most effective region where the variability of all parameters except step width and stride length decreased the most.



Figure 3. *The normalized trends of all gait parameters along the x-, y-, and z-axes for mean (upper) and variability (lower) gait parameters. The normalized trends are the result of normalization between parameters (Post-DBS minus Pre-DBS) to visualize the similarity of responses of different parameters to DBS treatment. The dashed line represents the median change (Post-DBS minus Pre-DBS) among patients.*

3.4 Most effective region for improved gait

The most effective regions for gait performance improvement were analysed separately for the variability and mean parameter groups. Only the parameters significantly affected by stimulation location according to the ANOVA performed were included in the analysed group, resulting in a reduced mean set that included only spatial parameters: step length, stride length, and walking speed, and a reduced variability set that included only temporal parameters: cadence, stride time, stance time, and step time. Due to its different response to location compared to the others (*c.f. Figure 3*), step width was not included in any group. The most effective region for the reduced mean set was defined as the voxel number where the maximum increase in parameters occurred, while for the reduced variability set, the location was chosen where the maximum decrease in variability occurred. The most effective regions for the two reduced sets were located within the STN but exhibited slight inter-group variations. Therefore, two most effective regions were defined, one for the reduced mean and one for the reduced variability set (*Figure 6C and D)*: The most effective region for the reduced mean set encompassed voxels (2,4,1), (2,3,1), (2,4,2), and (2,3,2), indicating active electrode contacts inside the STN along the y-axis posteriorly, along the z-axis superiorly and along the x-axis median line. In contrast, the most effective region for the reduced variability set comprised voxels (2,2,1) and (2,2,2), indicating active electrode contacts inside the STN along the y-axis anteriorly, along the z-axis superiorly and along the x-axis median line (centred on the medio-lateral axis).



Figure 4. *The normalized tendency of the (A) reduced mean set, and (B) reduced variability set, along with the average tendency for each subgroup and direction (black).*

3.5 The difference in stimulation location inside vs. outside the most effective region

The impact of the most effective region on both the mean and variability sets was analysed *(Table 5)*. In the mean set, patients with active contacts located inside the most effective region (inside subgroup), exhibited a greater increase in the means of stride length, step length, and walking speed after DBS treatment than those with active contacts located outside the effective region (outside subgroup). Interestingly, the inside subgroup also exhibited a greater decrease in variabilities of stance time, swing time, step length, step time, step width, and walking speed after DBS treatment than the outside subgroup, where the decreases in cadence and stride time were also significant. Moreover, for the inside subgroup, the variability of gait parameters decreased after the DBS surgery, instead of increasing, as seen for the average of the whole data set.

Table 5. *The average of gait parameters changes for patients with active contacts located in the most effective region (inside subgroup) and those without (outside subgroup) after DBS treatment. As long as the p-value for the difference in gait parameters between inside and outside subgroups. Bolded numbers are used to signify statistically significant differences.*

Parameters	**Mean Set**			**Variability Set**		
	Outside average	Inside average	*p-value*	Outside average	Inside average	*p-value*
Cadence	1.646	2.920	0.239	0.234	-0.534	**0.031**
DLST	0.001	-0.006	0.063	1.030	0.105	0.602
Stride Time	-0.015	-0.028	0.185	0.239	-0.513	**0.026**
Stance Time	-0.006	-0.020	0.077	0.357	-0.283	0.138
Swing Time	-0.009	-0.008	0.861	0.285	-0.340	0.214
Step Length	-2.627	0.425	**0.007**	0.260	-0.037	0.580
Step Time	-0.007	-0.014	0.240	0.254	-0.414	0.080
Step Width	0.512	0.353	0.657	-3.886	-10.927	0.158
Stride Length	-4.971	0.423	**0.014**	0.228	0.091	0.778
Walking Speed	-2.639	3.865	**0.010**	-0.070	-0.417	0.756

Discussion

This study aimed to evaluate the impact of STN-DBS treatment on gait performance in PwPD, to explore the correlations between treatment-related changes and stimulation location within the STN, as well as to define optimal DBS stimulation regions for maximizing overall gait performance. Our results revealed the following: 1) STN-DBS treatment can significantly decrease a patient's walking stride time, stance time, swing time and step time, as well as significantly increase stepping frequency, but with a compensatory increase in step width to maintain balance. In parallel, STN-DBS decreased the variability of step width, and increased the variability of DLST, stride time, stance time, and step time. 2) The location of active stimulation contacts can impact the average degree of gait change (step length, stride length, walking speed) and the variability of cadence, stride time, stance time, and step width. 3) The most effective region for improvements to mean step length, stride length, and walking speed is located inside the anterior, superior and central (mediolateral direction) STN. The most effective region for improvements to walking variability is inside the posterior, superior and central (mediolateral direction) STN.

4.1 The impact of STN-DBS on gait performance

Except for the parameter DLST, the average walking performance, as measured by temporal parameters, changed with STN-DBS to become non-significantly different compared to the performance of age-matched healthy participants. This indicates that STN-DBS treatment can enhance the recovery from pathological gait patterns caused by PD. However, when considering the effect size of STN-DBS on each parameter, our study reveals a range from small (Hedges' g = 0.2) to medium (Hedges' g = 0.5), despite being statistically significant according to the t-test. This suggests that the observed effect on each parameter might not be readily discernible to the human eye, yet the changes are also not so insignificant as to be negligible[25]. One potential explanation for this small-to-medium effect size could be the superposition of minor alterations in various gait parameters resulting from the overarching pathological walking pattern.

Our results demonstrated a significant decrease in stance time and swing time, consequently leading to a significant increase in cadence, indicative of faster stepping movements in patients with STN-DBS compared to their pre-treatment status. However, their overall walking speed remained constant. These results suggest that PwPD undergoing STN-DBS are capable of executing limb movements more rapidly. However, this increased speed comes at the expense of step length, resulting in quicker yet compensatory shorter steps and an augmented step width, maintaining a pathological walking pattern. Patients need to compensate for speed by widening their base of support to preserve balance. Hence, locomotor and balance training with PwPD after STN-DBS treatment can be strongly recommended to further enhance walking and balance abilities, supporting patients in adjusting to their new walking patterns, characterized by faster stepping facilitated by STN-DBS.

Much evidence has been presented to support the relationship between the variability of gait parameters and walking stability[26,27]. Elderly individuals physiologically exhibit higher step width variability compared to younger populations. Moreover, individuals with greater gait variability, regardless of spatial or temporal parameter domains, are more prone to falling during walking[28,29]. This observation can be explained by increased walking instability and susceptibility to external perturbations when a high level of variability exists. Conversely, low variability serves as an indicator of stable movement. Based on our results, all temporal parameters of variability as well as step and stride length variability increased after DBS treatment. This suggests that PwPD appear to exhibit heightened variability following DBS surgery, and specifically less walking stability in the anteroposterior direction. Looking at the broader perspective, the symptom of increased variability of gait parameters with STN-DBS treatment seems to indicate a general deterioration in walking performance, even though step width variability decreased and other clinical symptoms such as tremor and rigidity have improved.

4.2 The impact of stimulation contact location on gait outcome

This study demonstrates that the influence of stimulation location is notably pronounced in the mean value of gait parameters stride length, step length, and walking speed, and all of these parameters exhibit a comparable region of highest effectiveness. After surgery, the increase in these gait parameters reaches its maximum when the active contact is positioned on the superior, posterior, and central (medio-lateral) region of the STN. The most effective region identified in our study closely aligns with the sweet spot previously identified for optimally addressing rigidity and bradykinesia in PwPD (superior, posterior, medial)[16]. The alleviation of rigidity and bradykinesia symptoms can enhance a patient's ability to initiate and effectively exert movement, thereby improving walking ability[30-32]. This may explain why the most effective region for the mean value of spatial gait parameters overlaps with the sweet spot for relieving clinical symptoms such as rigidity and bradykinesia. The sweet spots located at the dorsal interface between the sensorimotor and associative regions of the STN have consistently demonstrated benefits for various motor functions in prior studies[12,17,33-37]. Anatomically, the most effective region for improving the mean value of spatial gait parameters has been shown to be the motor STN. In the current study, along the superior-inferior axis, stimulating inside the STN has been demonstrated to be better than stimulating outside and close to the thalamus. For the medial-lateral and anterior-posterior planes, the

best stimulation location has been suggested to be inside the STN in proximity to the substantia nigra.

In the variability set, stimulation location significantly influenced temporal parameters including cadence, stride time, step time, and stance time. All of these parameters suggest that stimulating the superior, anterior, and central region within the STN is most effective for decreasing gait variability towards physiological levels. The most effective region for lower gait variability identified in our study is in general agreement with the sweet spot that has been reported for improvement of tremor (superior, central in the antero-posterior direction, and lateral STN)[16]. In the elderly, lower variability in walking performance relates to a more stable gait pattern[24]. Previous meta-analyses have also indicated that the dorsolateral STN plays a crucial role in improving rigidity and bradykinesia[15,33]. Anatomically, the most effective region relating to decreased gait variability is also part of the motor STN. Based on the present data, the most effective region for stimulation along the superior-inferior axis is within the STN, as opposed to outside the STN near the thalamus. In terms of the medial-lateral and anterior-posterior planes, comparative data from both sides indicates that the most effective stimulation location is on the side of the globus pallidus adjacent to the STN, specifically at the connection between the STN and the internal segment of the globus pallidus.

In both the mean and variability sets, the most effective region on the mediolateral axis differs from the findings of previous studies. Our study suggests that PwPD can benefit significantly from having the central region of the STN stimulated, rather than focusing solely on either the medial or lateral side to address different symptoms. This distinction could potentially be attributed to the definition of voxels utilized in this research. On the mediolateral axis, the voxels were categorized as: completely outside the STN medially, partially within the STN medially, entirely within the central STN, partially within the STN laterally, and completely outside the STN laterally. Consequently, stimulation locations categorized as inside the STN - medially, centrally, and laterally were all grouped under the voxel classification of being entirely inside the centre of the STN. In this respect, a higher resolution analysis (i.e. exact anatomical location of the active contact) could help to elucidate the subtle differences between these regions.

4.3 The neurophysiological origin of the most effective stimulation location for gait

Movement generation is a highly complex process that involves the coordination of numerous spinal, bulbar, and suprabulbar structures. Among these structures, the basal ganglia of the motor circuit plays a significant role. Specifically, the STN assumes importance in the indirect pathway by transmitting inhibitory signals to the globus pallidus internal segment, thereby exerting inhibition over movement control[1]. Stimulation of the STN can help patients activate and re-calibrate the indirect pathway to better control their movements[6]. Hence, the most effective region for managing gait variability, situated within the globus pallidus side of the STN and encompassing the connection between the STN and the globus pallidus internal segment, delineates the precise location of the indirect pathway in the STN. Stimulation of this area may enable patients to potentially inhibit redundant movements during walking, thereby fostering a more stable gait pattern with reduced variability. Within the motor circuit, the pars reticulata, a component of the substantia nigra, assumes a crucial role in the direct pathway by continuously transmitting inhibitory signals to the thalamus to suppress

movement[1]. The substantia nigra-leaning side of the STN, identified as the most effective region in the mean set, likely represents the accurate location for the direct pathway linking the pars reticulata and the thalamus. Stimulation of this region blocks the direct pathway between the pars reticulata and the thalamus, thereby eliminating the inhibitory influence from the pars reticulata and enhancing the activation of movement. Consequently, patients may achieve a higher ability to initiate related movements, resulting in reduced bradykinesia, longer steps, and increased walking speed.

4.4 Limitations

In this study, the patient cohort size may be insufficient for conducting an extensive statistical analysis, particularly within a heterogeneous sample such as that recruited within this study. Furthermore, certain voxels that were included in the anatomical analysis lack representation within our sample. In addition, the visually based methodology used to identify the most effective region lacks precision and may need to be replaced by automated selection methods in future investigations.

4.5 Conclusions

Overall, STN-DBS treatment, from a macroscopic perspective, exacerbates the symptoms of unstable walking. However, when examining PwPD whose active contacts are situated anteriorly and superiorly within the STN, there is a slight improvement in walking performance following DBS treatment. The correlation observed between the location of active contacts for stimulation and gait improvement indicates that the means of specific spatio-temporal parameters, and the variability of temporal parameters are more responsive to the particular stimulation region than others. The region within the posterior, superior, and central STN has proven to be most effective in enhancing mean spatio-temporal parameters of walking, whereas the area contributing to improved gait variability lies within the anterior, superior, and central region of the STN. In conclusion, incorporating detailed pre-operative kinematic analysis alongside standard clinical tests for Parkinson's disease can now nicely assist in the planning of stereotactic surgery by targeting the active contact locations towards improving each patient’s predominant symptoms and individual pathology.

References

1 Poewe, W. *et al.* Parkinson disease. *Nat Rev Dis Primers* **3**, 17013, doi:10.1038/nrdp.2017.13 (2017).

2 Halliday, G. M. & McCann, H. The progression of pathology in Parkinson's disease. *Ann N Y Acad Sci* **1184**, 188-195, doi:10.1111/j.1749-6632.2009.05118.x (2010).

3 Bratsos, S., Karponis, D. & Saleh, S. N. Efficacy and Safety of Deep Brain Stimulation in the Treatment of Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Cureus* **10**, e3474, doi:10.7759/cureus.3474 (2018).

4 Ravi, D. K. *et al.* Does Subthalamic Deep Brain Stimulation Impact Asymmetry and Dyscoordination of Gait in Parkinson's Disease? *Neurorehabil Neural Repair* **35**, 1020-1029, doi:10.1177/15459683211041309 (2021).

5 Deuschl, G. & Agid, Y. Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits. *Lancet Neurol* **12**, 1025-1034, doi:10.1016/S1474-4422(13)70151-0 (2013).

6 Mahlknecht, P., Foltynie, T., Limousin, P. & Poewe, W. How Does Deep Brain Stimulation Change the Course of Parkinson's Disease? *Mov Disord* **37**, 1581-1592, doi:10.1002/mds.29052 (2022).

7 Collomb-Clerc, A. & Welter, M. L. Effects of deep brain stimulation on balance and gait in patients with Parkinson's disease: A systematic neurophysiological review. *Neurophysiol Clin* **45**, 371-388, doi:10.1016/j.neucli.2015.07.001 (2015).

8 Cossu, G. & Pau, M. Subthalamic nucleus stimulation and gait in Parkinson's Disease: a not always fruitful relationship. *Gait Posture* **52**, 205-210, doi:10.1016/j.gaitpost.2016.11.039 (2017).

9 Horn, A. *et al.* Lead-DBS v2: Towards a comprehensive pipeline for deep brain stimulation imaging. *Neuroimage* **184**, 293-316, doi:10.1016/j.neuroimage.2018.08.068 (2019).

10 Caire, F., Ranoux, D., Guehl, D., Burbaud, P. & Cuny, E. A systematic review of studies on anatomical position of electrode contacts used for chronic subthalamic stimulation in Parkinson's disease. *Acta Neurochir (Wien)* **155**, 1647-1654; discussion 1654, doi:10.1007/s00701-013-1782-1 (2013).

11 Zhang, F. *et al.* Relationship between electrode position of deep brain stimulation and motor symptoms of Parkinson's disease. *BMC Neurol* **21**, 122, doi:10.1186/s12883-021-02148-1 (2021).

12 Haegelen, C. *et al.* Functional atlases for analysis of motor and neuropsychological outcomes after medial globus pallidus and subthalamic stimulation. *PLoS One* **13**, e0200262, doi:10.1371/journal.pone.0200262 (2018).

13 Dembek, T. A. *et al.* Probabilistic sweet spots predict motor outcome for deep brain stimulation in Parkinson disease. *Ann Neurol* **86**, 527-538, doi:10.1002/ana.25567 (2019).

14 Reich, M. *et al.* Probabilistic mapping of gait changes after STNDBS for Parkinson’s disease. doi:10.21203/rs.3.rs-2353609/v1 (2022).

15 Boutet, A. *et al.* Sign-specific stimulation 'hot' and 'cold' spots in Parkinson's disease validated with machine learning. *Brain Commun* **3**, fcab027, doi:10.1093/braincomms/fcab027 (2021).

16 Akram, H. *et al.* Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson's disease. *Neuroimage* **158**, 332-345, doi:10.1016/j.neuroimage.2017.07.012 (2017).

17 Malaga, K. A., Costello, J. T., Chou, K. L. & Patil, P. G. Atlas-independent, N-of-1 tissue activation modeling to map optimal regions of subthalamic deep brain stimulation for Parkinson disease. *Neuroimage Clin* **29**, 102518, doi:10.1016/j.nicl.2020.102518 (2021).

18 König, N., Singh, N. B., von Beckerath, J., Janke, L. & Taylor, W. R. Is gait variability reliable? An assessment of spatio-temporal parameters of gait variability during continuous overground walking. *Gait & Posture* **39**, 615-617, doi:10.1016/j.gaitpost.2013.06.014 (2014).

19 Efron, B. a. R. T. An Introduction to the Bootstrap. (1994).

20 Ho, J., Tumkaya, T., Aryal, S., Choi, H. & Claridge-Chang, A. Moving beyond P values: data analysis with estimation graphics. *Nat Methods* **16**, 565-566, doi:10.1038/s41592-019-0470-3 (2019).

21 Enzmann, D. Notes on Effect Size Measures for the Difference of Means From Two Independent Groups: The Case of Cohen's d and Hedges' g. doi:10.13140/2.1.1578.2725 (2015).

22 Mirelman, A. *et al.* Gait impairments in Parkinson's disease. *Lancet Neurol* **18**, 697-708, doi:10.1016/S1474-4422(19)30044-4 (2019).

23 Iansek, M. E. M. H. M. D. The biomechanics and motor control of gait in Parkinson disease. (2001).

24 Konig, N., Taylor, W. R., Baumann, C. R., Wenderoth, N. & Singh, N. B. Revealing the quality of movement: A meta-analysis review to quantify the thresholds to pathological variability during standing and walking. *Neurosci Biobehav Rev* **68**, 111-119, doi:10.1016/j.neubiorev.2016.03.035 (2016).

25 Coe, R. It's the Effect Size, Stupid What effect size is and why it is important. (2012).

26 Skiadopoulos, A. & Stergiou, N. Risk-of-falling related outcomes improved in community-dwelling older adults after a 6-week sideways walking intervention: a feasibility and pilot study. *BMC Geriatr* **21**, 60, doi:10.1186/s12877-021-02010-6 (2021).

27 Yang, F. & Pai, Y. C. Can stability really predict an impending slip-related fall among older adults? *Journal of Biomechanics* **47**, 3876-3881, doi:10.1016/j.jbiomech.2014.10.006 (2014).

28 Hausdorff, J. M., Edelberg, H. K., Mitchell, S. L., Goldberg, A. L. & Wei, J. Y. Increased gait unsteadiness in community-dwelling elderly fallers. *Archives of Physical Medicine and Rehabilitation* **78**, 278-283, doi:Doi 10.1016/S0003-9993(97)90034-4 (1997).

29 Hausdorff, J. M., Rios, D. A. & Edelberg, H. K. Gait variability and fall risk in community-living older adults: A 1-year prospective study. *Archives of Physical Medicine and Rehabilitation* **82**, 1050-1056, doi:10.1053/apmr.2001.24893 (2001).

30 Buurke, T. J. W., van de Venis, L., Keijsers, N. & Nonnekes, J. The effect of walking with reduced trunk motion on dynamic stability in healthy adults. *Gait Posture* **103**, 113-118, doi:10.1016/j.gaitpost.2023.05.004 (2023).

31 Dotov, D., Cochen de Cock, V., Driss, V., Bardy, B. & Dalla Bella, S. Coordination Rigidity in the Gait, Posture, and Speech of Persons with Parkinson's Disease. *J Mot Behav* **55**, 394-409, doi:10.1080/00222895.2023.2217100 (2023).

32 Onder, H., Dinc, E., Yucesan, K. & Comoglu, S. The gait parameters in patients with Parkinson's Disease under STN-DBS therapy and associated clinical features. *Neurol Res* **45**, 779-785, doi:10.1080/01616412.2023.2208478 (2023).

33 Butson, C. R., Cooper, S. E., Henderson, J. M., Wolgamuth, B. & McIntyre, C. C. Probabilistic analysis of activation volumes generated during deep brain stimulation. *Neuroimage* **54**, 2096-2104, doi:10.1016/j.neuroimage.2010.10.059 (2011).

34 Conrad, E. C., Mossner, J. M., Chou, K. L. & Patil, P. G. Atlas-Independent, Electrophysiological Mapping of the Optimal Locus of Subthalamic Deep Brain Stimulation for the Motor Symptoms of Parkinson Disease. *Stereotact Funct Neurosurg* **96**, 91-99, doi:10.1159/000486643 (2018).

35 Herzog, J. *et al.* Most effective stimulation site in subthalamic deep brain stimulation for Parkinson's disease. *Mov Disord* **19**, 1050-1054, doi:10.1002/mds.20056 (2004).

36 Maks, C. B., Butson, C. R., Walter, B. L., Vitek, J. L. & McIntyre, C. C. Deep brain stimulation activation volumes and their association with neurophysiological mapping and therapeutic outcomes. *J Neurol Neurosurg Psychiatry* **80**, 659-666, doi:10.1136/jnnp.2007.126219 (2009).

37 Yokoyama, T., Ando, N., Sugiyama, K., Akamine, S. & Namba, H. Relationship of stimulation site location within the subthalamic nucleus region to clinical effects on parkinsonian symptoms. *Stereotact Funct Neurosurg* **84**, 170-175, doi:10.1159/000094956 (2006).